Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | GPR52 | Q9Y2T5 | 6/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229813 | 0.85 | PTGER4 (0.48) | PTGER4PTGER2ARTAAR1LTA4H | |
| SCHEMBL13655991 | 0.80 | PTGER4 (0.48) | PTGER4PTGER2GPR52TAAR1IDO1 | |
| SCHEMBL13656014 | 0.79 | PTGER4 (0.48) | PTGER4PTGER2HTR2AHTR2CHTR2B | |
| SCHEMBL18002661 | 0.73 | MAPT (0.46) | HTR2AHTR2CHTR2BTAAR1LTA4H | |
| SCHEMBL13656002 | 0.71 | PTGER4 (0.45) | PTGER4PTGER2HTR2AHTR2BAR | |
| SCHEMBL30644998 | 0.71 | DAO (0.49) | HTR2AHTR2CHTR2BTAAR1LTA4H | |
| SCHEMBL18001841 | 0.71 | DAO (0.49) | HTR2AHTR2CHTR2BTAAR1LTA4H | |
| SCHEMBL17508140 | 0.71 | LTA4H (0.50) | HTR2AHTR2CHTR2BTAAR1LTA4H | |
| SCHEMBL3237564 | 0.71 | TAAR1 (0.64) | HTR2AHTR2CHTR2BTAAR1LTA4H | |
| SCHEMBL28291656 | 0.70 | TAAR1 (0.56) | HTR2AHTR2CHTR2BTAAR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885HTR2A 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.